Helius Medical Technologies Inc (HSDT)

[ALERTS100%to10000%GAIN]

on L2 very ,very thin now to.99

[ALERTS100%to10000%GAIN]

will be good here

[Tobster3344]

A Lot of Dumping now.....

[Tobster3344]

A Lot of Dumping now.....

[ALERTS100%to10000%GAIN]

Helius Medical Technologies shares are trading higher after the company announced results from an independent research study showed positive results on translingual neurostimulation plus physical therapy with significant improvement in balance and gait.

Dec 19, 2019 11:03a ETBenzinga Stock Analysis

[ALERTS100%to10000%GAIN]

today is the highest volume for HSDT https://finance.yahoo.com/quote/HSDT/history?p=HSDT

[ALERTS100%to10000%GAIN]

.685 wall fall and run after

[ALERTS100%to10000%GAIN]

looking close to .80

[ALERTS100%to10000%GAIN]

.5731 low of the day,holding great and breakout ahead

[ALERTS100%to10000%GAIN]

holding my for dollars,great inside info

[Tobster3344]

I am new at this stock as of today. Kinda nervous getting in late after the spike. Where do you guys this this will end up today? Just a one day run or is there something here worth staying?

[ALERTS100%to10000%GAIN]

will be a nice close

[ALERTS100%to10000%GAIN]

loaded at .64 again

[tykundegex]

Third party validation is crucial IMO, and this study echoes the findings of previous studies. But it does not draw a comparison between PoNS with PT and PT alone. However I find this requirement (imposed by FDA for before granting 510k for PoNS) to be superfluous given that both this and prior studies clearly stated that all participants "had seen little progress or had plateaued in their recovery with PT", implying that PT alone will not benefit the patients further.

Here is the partial PR, with emphasis added.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (the “Company”), a neurotech company focused on neurological wellness, announced today that the results from independent research conducted at the University of Wisconsin-Madison on translingual neurostimulation for the treatment of chronic symptoms due to mild-to moderate traumatic brain injury (“mmTBI”) have been published in the December 2019 issue of the Archives of Rehabilitation Research and Clinical Translation. For more information on the trial and its results, see the published journal article.
The newly published results from the double-blind randomized clinical trial which paired translingual neurostimulation using the Portable Neuromodulation Stimulator (PoNS™) device with therapeutic activities, showed significantly improved balance and gait scores over the 14-week treatment period and the outcomes were sustained for 12 weeks after discontinuing the treatment.

“Traumatic brain injuries are rising steadily in North America and whether these injuries are mild or moderate, the effects can last a lifetime,” said Philippe Deschamps, Chief Executive Officer of Helius Medical Technologies. “The results from this independent clinical trial provide clinical support for the PoNS Treatment™ as an effective treatment option for patients suffering from the effects of mmTBI and we are excited to have the validation of the data in a peer reviewed publication.”

The trial evaluated 43 participants who had experienced an mmTBI at least one year prior to receiving the PoNS Treatment and had seen little progress or had plateaued in their recovery with physical therapy. Researchers found that approximately 74 percent of the participants who completed the 14 weeks of PoNS Treatment experienced significant improvements in their balance. Patients also showed meaningful improvements in their gait and walking endurance.

Exploratory endpoints, such as headache burden and sleep quality, were also observed as part of the trial. While further analysis and research is needed, there was an indication of improvement in these exploratory endpoints. The demonstrated improvements in balance and gait, coupled with potential improvements in the exploratory endpoints may allow treated individuals to experience a better quality of life.

[420man]

Bull up on news...Bear back down to support...Bull back up to test resistance... Clockwork :)

[whytestocks]

News: $HSDT Independent Research Published Show Positive Results on Translingual Neurostimulation Plus Physical Therapy With Statistically Significant Improvement in Balance and Gait Scores and the Outcomes Were Sustained for 12 Weeks After Discontinuing Treatment

NEWTOWN, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (the “Company”), a neurotech company focused on neurological wellness, announced today that the results from independent research conducted at the University of Wisconsin-...

Read the whole news HSDT - Independent Research Published Show Positive Results on Translingual Neurostimulation Plus Physical Therapy With Statistically Significant Improvement in Balance and Gait Scores and the Outcomes Were Sustained for 12 Weeks After Discontinuing Treatment

[yankees18]

Squeeze

[420man]

Stopped out on that dip. Waiting for direction

[420man]

Peeps are still playing with naked pics... LOL

[ALERTS100%to10000%GAIN]

will see,we need green here

[420man]

Opening bell should be very interesting.

[ALERTS100%to10000%GAIN]

HSDT~~could be a crazy run,bottom chart
https://www.stockscores.com/charts/charts/?ticker=hsdt

[420man]

Agreed. Will add on any significant dip. GL

[ALERTS100%to10000%GAIN]

342k volume,very thin low shares left

[ALERTS100%to10000%GAIN]

great news here Helius Medical Technologies Inc. (HSDT) shares more than doubled premarket to 88 cents.
The neurotech company said results from independent research conducted at the University of Wisconsin-Madison on translingual neurostimulation for the treatment of chronic symptoms due to mild-to moderate traumatic brain injury were published in the December 2019 issue of the Archives of Rehabilitation Research and Clinical Translation.
The newly-published results from the double-blind randomized clinical trial which paired translingual neurostimulation using the Portable Neuromodulation Stimulator device with therapeutic activities, showed significantly improved balance and gait scores over the 14-week treatment period and the outcomes were sustained for 12 weeks after discontinuing the treatment, the company said.
The trial evaluated 43 participants. Researchers found about 74% of the participants who completed the 14 weeks of PoNS Treatment experienced significant improvements in their balance, the company said. Patients also showed meaningful improvements in their gait and walking endurance.

Write to Michael Dabaie at [e-mail]

[420man]

Bounce from here. Almost a Milly short. That's 600K left to cover on buying pressure

[ALERTS100%to10000%GAIN]

very violative

[420man]

Reloaded a few @ .76. Only 250k shares traded so far...expecting more momo as news spreads.

[ALERTS100%to10000%GAIN]

will be hart to buy again if does't go down

[ALERTS100%to10000%GAIN]

great

[420man]

.61 to .90 in 5 minutes...

[ALERTS100%to10000%GAIN]

HSDT is in a share class of common stock
Float
23.7M
Shares Outstanding
30.7M
Institutions Holding Shares
29
% Held by Institutions
10.66%

[ALERTS100%to10000%GAIN]

sold?

[ALERTS100%to10000%GAIN]

only 120k volume

[420man]

Looking for pullback to reload...

[ALERTS100%to10000%GAIN]

very thin

[yankees18]

Not many shares available

[ALERTS100%to10000%GAIN]

will be multi dollars here,oversold ,news are great

[ALERTS100%to10000%GAIN]

52-Wk Range0.28 - 9.57

[ALERTS100%to10000%GAIN]

nice

[yankees18]

Got .53....

[ALERTS100%to10000%GAIN]

bought at .73

[420man]

Was able to grab .61

[tykundegex]

Q3 earnings call scheduled for 8am ET Nov 11. Their prev revenue guidance was $1.2 - $2MM for 2019, based on their initial 2 Canadian clinics. They just announced the opening of their fifth. If they increase their guidance and show real traction, I will definitely take advantage of the all-time lows we are seeing lately, and take out a larger position. We should also be hearing soon about CE mark and Australian clearance. And hopefully an update on the path to FDA approval.

[tykundegex]

and an open label study showing transcranial EM stimulation could help Alzheimers patients:

https://www.medicalnewstoday.com/articles/326401.php

https://www.neuroem.com/

[tykundegex]

There is a lot of noise out there (esp on social media) about how PoNS is a scam, so I though I'd include a few other unrelated resources about different applications of neurostimulation in general:

UK company with FDA cleared device to alleviate migraines:
https://www.gammacore.com/

Study about stimulating creativity:
https://www.economist.com/science-and-technology/2019/06/15/zapping-the-brain-improves-creativity
https://www.sciencedaily.com/releases/2016/04/160414095949.htm

For Epilepsy:
https://www.sciencedaily.com/releases/2016/09/160919220132.htm

For Schizophrenia:
https://www.sciencedaily.com/releases/2015/05/150527180148.htm

[tykundegex]

Quick summary of Helius Medical:

first and only solution indicated for mmTBI
pilot studies for MS, CP, stroke..all with similar results across all symptoms
350k Canadians with mmTBI
1.5MM Americans
120k new cases every year in USA
product stimulates trigeminal nerve via tongue
IP whitespace (tongue-based brain stimulation entirely unexplored before today)
60 patents covering method and utility
increases blood supply to brain
neuromodulation combined with phsy/cog therapy leads to brain rebuilding itself (neurplasticity)
shown efficacious on patients who have undergone every other available therapy, and are no longer improving, even after an average of 4 years since last treatment
study was patients who are all treatment resistant and min 1 year later (chronic symptoms set in, lifetime affliction virtual certainty)
120 person trial
50% of them regained normal balance after the trial
efficacy retained 3mo after last use of device, proving the remedy is permanent
Cleared in Canada, commercialization underway
cleared in Russia (partners in place)
EU clearance submission filed in Dec 2018
AU submitted in May 2019
expect AU verdict in summer 2019
FDA rejected "de novo" classification, so back to FDA around Sept to get detailed guidance
not waiting.. generating a random PT-only trial now
Canada alone is "multi-billion dollar business" just for mmTBI indication
device sales is focus, partners and clinic drive service
2 founding clinics in CA
3 more clinics in CA just signed (now over 50% of population have access)
*data due in summer about patient outcomes*, prelim is encouraging

PoNS is a platform tech
peer-reviewed studies on MS
AU publication on stroke
other neurological conditions likely
$19MM in cash at the end of Q1
$700k in revenue last year
2019 guidance: $1.6-2MM in revenue from the 2 initial CA clinics alone (though they already signed 3 more)
early Aug will report Q2 numbers and update guidance

JMP Conference webcast from June 2019: http://wsw.com/webcast/jmp39/hsdt/index.aspx
Latest Investor deck: https://heliusmedical.com/images/pdf/Presentation/2019/HSDT_Company_Public_Presentation_v_2.1_MLR_Approved_5232019.pdf
Video supposedly showing one child's result from PoNS treatment in Russia: https://vimeo.com/181665292
and to offer an alternative perspective, a bearish SA article from Jan: https://seekingalpha.com/article/4234256-helius-medical-failed-clinical-trial-redacted-data-questionable-leadership-points-ineffective

[whytestocks]

News: $HSDT Helius Medical Technologies, Inc. Provides a Business Update on FDA Strategy

NEWTOWN, Pa., June 18, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today is providing an update on its strategy to resubmit an application fo...

Read the whole news https://marketwirenews.com/news-releases/helius-medical-technologies-inc-provides-a-business-update-on-fda-strategy-8373252.html

[whytestocks]

News: $HSDT Helius Medical Technologies, Inc. Announces Addition of Three New PoNS(TM) Authorized Clinics in Canada

NEWTOWN, Pa., June 05, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported that three new clinics have been authorized to provide PoNS...

Got this from https://marketwirenews.com/news-releases/helius-medical-technologies-inc-announces-addition-of-three-new-pons-tm-authorized-clinics-in-canada-8302102.html

[stock1ace1]

Breakout !! Open gap